New Product - Xeomin
Xeomin (incobotulinumtoxinA) is produced from the fermentation of Clostridium botulinum and is subsequently purified to remove complexing proteins. IncobotulinumtoxinA blocks cholinergic transmission at the neuromuscular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve terminals. Xeomin is indicated for use for the treatment of cervical dystonia in adults; blepharospasm in adults; post-stroke spasticity of the upper limb in adults; and in glabellar frown lines in adults. Xeomin is contraindicated in generalised disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome) and in infection or inflammation at the proposed injection sites. Xeomin is available as 50 LD50 units and 100 LD50 units in single glass vials.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629